vinorelbine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
vinca alkaloids	2827	71486-22-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: vinorelbin ditartrate noranhydrovinblastine tartrate vinorelbine navelbin navelbine base 5'-anhydrovinblastine vinorelbine tartrate vinorelbine ditartrate navelbine vinorelbine base	A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES. Molecular weight: 778.95 Formula: C45H54N4O8 CLOGP: 5.94 LIPINSKI: 3 HAC: 12 HDO: 2 TPSA: 133.87 ALOGS: -4.81 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

vinorelbin ditartrate
noranhydrovinblastine tartrate
vinorelbine
navelbin
navelbine base
5'-anhydrovinblastine
vinorelbine tartrate
vinorelbine ditartrate
navelbine
vinorelbine base

A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES.

Molecular weight: 778.95
Formula: C45H54N4O8
CLOGP: 5.94
LIPINSKI: 3
HAC: 12
HDO: 2
TPSA: 133.87
ALOGS: -4.81
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1000 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	11 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	27 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	23 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	20 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.87 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	26 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 23, 1994	FDA	PIERRE FABRE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	740.10	22.47	372	14902	73215	56203578
Disease progression	597.55	22.47	365	14909	104808	56171985
Metastases to liver	412.71	22.47	171	15103	21415	56255378
Metastases to bone	398.33	22.47	162	15112	19346	56257447
Neutropenia	392.91	22.47	332	14942	157835	56118958
Breast cancer metastatic	341.81	22.47	136	15138	15333	56261460
Palmar-plantar erythrodysaesthesia syndrome	298.14	22.47	135	15139	20930	56255863
Metastases to lung	251.79	22.47	101	15173	11617	56265176
Neoplasm progression	214.77	22.47	124	15150	31892	56244901
Metastases to lymph nodes	198.49	22.47	75	15199	7348	56269445
Mucosal inflammation	188.81	22.47	127	15147	42683	56234110
Breast cancer	166.95	22.47	124	15150	48709	56228084
Metastases to central nervous system	159.77	22.47	74	15200	12062	56264731
Neuropathy peripheral	142.60	22.47	157	15117	102736	56174057
PIK3CA-activated mutation	117.51	22.47	31	15243	927	56275866
Febrile neutropenia	114.42	22.47	142	15132	105403	56171390
Pleural effusion	99.09	22.47	119	15155	85361	56191432
Breast cancer recurrent	97.56	22.47	38	15236	4037	56272756
Osteonecrosis of jaw	92.79	22.47	75	15199	33283	56243510
Haematotoxicity	91.65	22.47	45	15229	8338	56268455
Ejection fraction decreased	90.14	22.47	60	15214	19781	56257012
Metastases to peritoneum	89.98	22.47	33	15241	2971	56273822
Thrombocytopenia	78.46	22.47	136	15138	136088	56140705
Tonsillar disorder	77.45	22.47	23	15251	1067	56275726
Myelosuppression	72.64	22.47	50	15224	17405	56259388
Blood uric acid decreased	71.97	22.47	20	15254	730	56276063
Eosinophil percentage increased	66.21	22.47	20	15254	984	56275809
Polyneuropathy	65.47	22.47	42	15232	13008	56263785
Neurotoxicity	65.15	22.47	45	15229	15750	56261043
Ascites	63.90	22.47	64	15210	37480	56239313
Metastases to skin	62.82	22.47	21	15253	1437	56275356
Fall	60.16	22.47	12	15262	357498	55919295
Nasal disorder	58.02	22.47	23	15251	2559	56274234
Bone marrow failure	57.16	22.47	53	15221	28233	56248560
Off label use	55.02	22.47	296	14978	555884	55720909
EGFR gene mutation	53.52	22.47	13	15261	276	56276517
Death	52.50	22.47	207	15067	341219	55935574
Drug hypersensitivity	51.25	22.47	7	15267	275198	56001595
Neutropenic sepsis	50.58	22.47	38	15236	15147	56261646
Joint swelling	50.28	22.47	9	15265	289791	55987002
Osteonecrosis	44.03	22.47	42	15232	23173	56253620
Tumour marker increased	43.83	22.47	22	15252	4271	56272522
Decreased appetite	42.14	22.47	143	15131	219088	56057705
Skin toxicity	41.57	22.47	21	15253	4132	56272661
Therapy partial responder	41.40	22.47	26	15248	7759	56269034
Hepatotoxicity	40.43	22.47	46	15228	31107	56245686
Second primary malignancy	40.06	22.47	25	15249	7377	56269416
Leukopenia	39.71	22.47	70	15204	70870	56205923
Vessel puncture site bruise	39.23	22.47	11	15263	415	56276378
Peripheral sensory neuropathy	38.93	22.47	24	15250	6932	56269861
Hiccups	38.79	22.47	16	15258	1972	56274821
Lymphangiosis carcinomatosa	38.44	22.47	14	15260	1235	56275558
Blood creatinine decreased	37.26	22.47	21	15253	5145	56271648
Arthralgia	35.29	22.47	51	15223	501618	55775175
Hyperchlorhydria	34.94	22.47	14	15260	1601	56275192
Abdominal discomfort	34.58	22.47	16	15258	277258	55999535
Cardiotoxicity	34.41	22.47	23	15251	7627	56269166
Joint neoplasm	34.39	22.47	7	15267	63	56276730
Superior vena cava syndrome	34.38	22.47	11	15263	655	56276138
Metastatic neoplasm	34.02	22.47	18	15256	3895	56272898
Gastrointestinal toxicity	33.84	22.47	21	15253	6135	56270658
Hypothalamo-pituitary disorder	33.84	22.47	11	15263	689	56276104
Mediastinum neoplasm	33.81	22.47	7	15267	69	56276724
Soft tissue neoplasm	33.54	22.47	7	15267	72	56276721
Metastases to meninges	33.51	22.47	15	15259	2255	56274538
Injection site extravasation	33.00	22.47	23	15251	8161	56268632
Hormone receptor positive breast cancer	32.91	22.47	10	15264	502	56276291
Blood lactate dehydrogenase increased	32.90	22.47	34	15240	20641	56256152
Metastases to chest wall	32.81	22.47	10	15264	507	56276286
Maternal exposure during pregnancy	32.61	22.47	6	15268	189547	56087246
Metastases to spine	32.53	22.47	16	15258	2973	56273820
Transaminases	32.48	22.47	7	15267	85	56276708
Disease recurrence	32.27	22.47	36	15238	23824	56252969
Diarrhoea	32.06	22.47	288	14986	638219	55638574
Desmoplastic small round cell tumour	31.88	22.47	8	15266	195	56276598
Invasive ductal breast carcinoma	31.86	22.47	21	15253	6805	56269988
Osteolysis	31.50	22.47	15	15259	2598	56274195
Pituitary tumour	31.39	22.47	11	15263	868	56275925
Acquired gene mutation	31.29	22.47	11	15263	876	56275917
Metastasis	30.64	22.47	18	15256	4766	56272027
Constipation	30.60	22.47	122	15152	201821	56074972
Sinusitis	30.46	22.47	8	15266	197573	56079220
Diffuse large B-cell lymphoma recurrent	30.46	22.47	13	15261	1744	56275049
Hepatic enzyme increased	30.41	22.47	5	15269	171379	56105414
Pruritus	30.17	22.47	25	15249	316598	55960195
Metastases to pleura	29.97	22.47	12	15262	1370	56275423
Nail infection	29.87	22.47	14	15260	2339	56274454
Nausea	29.79	22.47	327	14947	763851	55512942
Condition aggravated	29.59	22.47	30	15244	344868	55931925
Urticaria	28.58	22.47	3	15271	144673	56132120
Jaw operation	27.99	22.47	10	15264	835	56275958
Stomatitis	27.91	22.47	84	15190	120726	56156067
Pancytopenia	27.80	22.47	69	15205	88646	56188147
Folate deficiency	27.78	22.47	13	15261	2164	56274629
Anaemia	26.72	22.47	143	15131	267368	56009425
Musculoskeletal stiffness	26.70	22.47	5	15269	156002	56120791
Asthenia	26.30	22.47	171	15103	342802	55933991
Gene mutation	26.04	22.47	11	15263	1438	56275355
Gingival bleeding	25.79	22.47	23	15251	11643	56265150
Lymphoedema	25.78	22.47	22	15252	10508	56266285
Dermatitis exfoliative generalised	24.93	22.47	14	15260	3406	56273387
Cardiac cirrhosis	24.46	22.47	6	15268	133	56276660
Drug resistance	24.42	22.47	29	15245	20513	56256280
Toothache	24.22	22.47	27	15247	17853	56258940
Nail avulsion	24.00	22.47	6	15268	144	56276649
Scintillating scotoma	23.77	22.47	6	15268	150	56276643
Eosinophil count increased	23.32	22.47	20	15254	9617	56267176
Weight increased	23.31	22.47	17	15257	229686	56047107
Hypertransaminasaemia	23.23	22.47	15	15259	4692	56272101
Vascular device infection	23.22	22.47	16	15258	5574	56271219
Postictal state	23.12	22.47	9	15265	954	56275839
Mediastinal disorder	22.85	22.47	7	15267	361	56276432
Odynophagia	22.56	22.47	17	15257	6801	56269992

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neutropenia	116.53	26.28	109	3536	140255	31553444
Febrile neutropenia	72.23	26.28	79	3566	121770	31571929
Disease progression	66.77	26.28	66	3579	90398	31603301
Off label use	64.51	26.28	130	3515	347144	31346555
Malignant neoplasm progression	62.71	26.28	60	3585	78938	31614761
Neutropenic sepsis	59.94	26.28	29	3616	12350	31681349
Febrile bone marrow aplasia	55.72	26.28	24	3621	7822	31685877
Pneumonitis	46.72	26.28	34	3611	30618	31663081
Neoplasm progression	39.11	26.28	26	3619	20246	31673453
Myelosuppression	38.48	26.28	23	3622	14897	31678802
Toxic erythema of chemotherapy	37.97	26.28	7	3638	92	31693607
Metastases to lung	35.61	26.28	18	3627	8404	31685295
Leukopenia	33.28	26.28	37	3608	57791	31635908
Product use in unapproved indication	32.58	26.28	48	3597	99123	31594576
Product leakage	32.20	26.28	8	3637	453	31693246
Interstitial lung disease	29.82	26.28	36	3609	61367	31632332
Hypophosphataemia	29.71	26.28	16	3629	8498	31685201
Diffuse large B-cell lymphoma refractory	29.66	26.28	9	3636	1074	31692625
Agranulocytosis	28.85	26.28	22	3623	21225	31672474
Pancytopenia	28.28	26.28	42	3603	87274	31606425
Thrombocytopenia	26.91	26.28	54	3591	142693	31551006

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	505.06	20.68	315	14550	121424	70792155
Neutropenia	348.53	20.68	343	14522	256813	70656766
Disease progression	323.04	20.68	265	14600	156407	70757172
Metastases to bone	242.13	20.68	110	14755	22266	70891313
Breast cancer metastatic	223.49	20.68	83	14782	10063	70903516
Metastases to lung	213.67	20.68	92	14773	16392	70897187
Metastases to liver	203.03	20.68	102	14763	25776	70887803
Neoplasm progression	202.18	20.68	123	14742	45105	70868474
Palmar-plantar erythrodysaesthesia syndrome	163.38	20.68	93	14772	30154	70883425
Mucosal inflammation	150.54	20.68	120	14745	67730	70845849
Neuropathy peripheral	127.99	20.68	145	14720	126751	70786828
Febrile neutropenia	124.83	20.68	182	14683	204136	70709443
Metastases to lymph nodes	121.13	20.68	52	14813	9186	70904393
Neutropenic sepsis	114.69	20.68	69	14796	24761	70888818
Myelosuppression	102.41	20.68	69	14796	30076	70883503
Breast cancer	100.35	20.68	71	14794	33478	70880101
Metastases to central nervous system	99.83	20.68	53	14812	14981	70898598
Breast cancer recurrent	96.66	20.68	32	14833	2761	70910818
Tonsillar disorder	83.24	20.68	23	14842	1071	70912508
Osteonecrosis of jaw	81.37	20.68	68	14797	40934	70872645
PIK3CA-activated mutation	77.32	20.68	19	14846	555	70913024
Haematotoxicity	71.01	20.68	41	14824	13633	70899946
Bone marrow failure	65.30	20.68	65	14800	48945	70864634
Ejection fraction decreased	65.17	20.68	53	14812	30709	70882870
Blood uric acid decreased	63.43	20.68	19	14846	1181	70912398
Thrombocytopenia	62.71	20.68	148	14717	238962	70674617
Febrile bone marrow aplasia	62.38	20.68	36	14829	11955	70901624
Metastases to peritoneum	61.86	20.68	25	14840	3794	70909785
Eosinophil percentage increased	59.89	20.68	19	14846	1431	70912148
Nasal disorder	58.21	20.68	23	14842	3291	70910288
Off label use	55.83	20.68	304	14561	742756	70170823
Therapy partial responder	53.32	20.68	33	14832	12441	70901138
EGFR gene mutation	52.31	20.68	13	14852	398	70913181
Fall	50.90	20.68	15	14850	444081	70469498
Pancytopenia	46.81	20.68	100	14765	151007	70762572
Pleural effusion	43.56	20.68	90	14775	132774	70780805
Pneumonitis	42.86	20.68	55	14810	54542	70859037
Metastases to skin	42.62	20.68	15	14850	1556	70912023
Neurotoxicity	42.41	20.68	41	14824	29785	70883794
Peripheral sensory neuropathy	41.78	20.68	28	14837	12082	70901497
Vessel puncture site bruise	40.59	20.68	11	14854	476	70913103
Hormone receptor positive breast cancer	39.72	20.68	10	14855	323	70913256
Polyneuropathy	39.37	20.68	34	14831	21381	70892198
Metastases to spine	38.80	20.68	18	14847	3811	70909768
Joint neoplasm	36.19	20.68	7	14858	63	70913516
Hepatotoxicity	35.61	20.68	45	14820	43941	70869638
Leukopenia	34.70	20.68	72	14793	106488	70807091
Invasive ductal breast carcinoma	34.43	20.68	19	14846	5790	70907789
Nail infection	34.31	20.68	14	14851	2177	70911402
Soft tissue neoplasm	34.28	20.68	7	14858	85	70913494
Agranulocytosis	33.85	20.68	42	14823	40256	70873323
Hyperchlorhydria	33.08	20.68	13	14852	1833	70911746
Blood creatinine decreased	32.83	20.68	20	14845	7329	70906250
Desmoplastic small round cell tumour	32.74	20.68	8	14857	228	70913351
Lymphangiosis carcinomatosa	32.71	20.68	13	14852	1888	70911691
Injection site extravasation	32.06	20.68	21	14844	8725	70904854
Hypothalamo-pituitary disorder	31.80	20.68	11	14854	1084	70912495
Drug hypersensitivity	31.66	20.68	8	14857	262451	70651128
Nausea	31.61	20.68	294	14571	851794	70061785
Pituitary tumour	31.26	20.68	11	14854	1140	70912439
Arthralgia	30.96	20.68	36	14829	503354	70410225
Metastases to the mediastinum	30.44	20.68	9	14856	535	70913044
Metastatic neoplasm	29.76	20.68	16	14849	4632	70908947
Disease recurrence	29.69	20.68	38	14827	37565	70876014
Transaminases	29.08	20.68	6	14859	77	70913502
Blood lactate dehydrogenase increased	28.53	20.68	36	14829	35091	70878488
Mediastinum neoplasm	28.21	20.68	6	14859	90	70913489
Acquired gene mutation	28.12	20.68	12	14853	2086	70911493
Constipation	28.11	20.68	116	14749	252322	70661257
Decreased appetite	27.85	20.68	132	14733	304648	70608931
Non-small cell lung cancer recurrent	27.67	20.68	6	14859	99	70913480
Gingival bleeding	27.62	20.68	24	14841	15208	70898371
Gastrointestinal toxicity	27.51	20.68	17	14848	6388	70907191
Nail avulsion	27.29	20.68	6	14859	106	70913473
Toxic erythema of chemotherapy	27.26	20.68	7	14858	245	70913334
Osteonecrosis	27.11	20.68	32	14833	29128	70884451
Gene mutation	27.11	20.68	12	14853	2279	70911300
Tumour marker increased	26.96	20.68	14	14851	3780	70909799
Jaw operation	26.81	20.68	9	14856	810	70912769
Joint swelling	26.44	20.68	10	14855	253201	70660378
Diarrhoea	26.41	20.68	265	14600	783076	70130503
Stomatitis	25.80	20.68	72	14793	128439	70785140
Poor peripheral circulation	25.16	20.68	13	14852	3472	70910107
Non-small cell lung cancer	25.13	20.68	16	14849	6331	70907248
Ascites	24.81	20.68	48	14817	67499	70846080
Hypotension	24.76	20.68	29	14836	404352	70509227
Drug resistance	24.67	20.68	35	14830	38155	70875424
Vaginal discharge	24.59	20.68	14	14851	4529	70909050
Folate deficiency	23.91	20.68	12	14853	3018	70910561
Primary mediastinal large B-cell lymphoma	23.76	20.68	5	14860	71	70913508
Lower limb fracture	23.73	20.68	23	14842	16749	70896830
Toothache	23.72	20.68	24	14841	18406	70895173
Scintillating scotoma	23.45	20.68	6	14859	207	70913372
Skin toxicity	23.30	20.68	16	14849	7182	70906397
Cardiotoxicity	23.28	20.68	19	14846	11051	70902528
Cardiac cirrhosis	23.15	20.68	6	14859	218	70913361
Hypertransaminasaemia	22.37	20.68	17	14848	8926	70904653
Cough	22.20	20.68	130	14735	325247	70588332
Nail disorder	22.15	20.68	18	14847	10406	70903173
Asthenia	21.69	20.68	167	14698	457499	70456080
Urticaria	21.62	20.68	4	14861	163045	70750534
Acute myeloid leukaemia	20.94	20.68	29	14836	30911	70882668
Anaemia	20.69	20.68	150	14715	403273	70510306

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01CA04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS Vinca alkaloids and analogues
FDA CS	M0022674	Vinca Alkaloids
MeSH PA	D050256	Antimitotic Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000972	Antineoplastic Agents, Phytogenic
MeSH PA	D050257	Tubulin Modulators
FDA EPC	N0000175612	Vinca Alkaloid
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:47868	photosensitising agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Non-small cell lung cancer	indication	254637007	DOID:3908
Kaposi's sarcoma	off-label use	109385007
Neoplasm of endometrium	off-label use	123844007	DOID:1380
Small cell carcinoma of lung	off-label use	254632001	DOID:5409
Metastatic Breast Carcinoma	off-label use
Disorder of lung	contraindication	19829001	DOID:850
Infectious disease	contraindication	40733004
Gastrointestinal perforation	contraindication	51875005
Hepatic failure	contraindication	59927004
Interstitial pneumonia	contraindication	64667001
Intestinal obstruction	contraindication	81060008	DOID:8437
Leukopenia	contraindication	84828003	DOID:615
Gastrointestinal obstruction	contraindication	126765001
Pregnancy, function	contraindication	289908002
Bone marrow depression	contraindication	307762000
Breastfeeding (mother)	contraindication	413712001
Hepatic Metastases	contraindication
Intestinal Ischemic Necrosis	contraindication
Severe Granulocytopenia	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.32	acidic
pKa2	13.35	acidic
pKa3	8.55	Basic
pKa4	7.39	Basic
pKa5	6.11	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Tubulin beta	Tumour-associated antigen	P07437 Q9H4B7 Q13885 Q9BVA1 Q13509 P04350 P68371 Q9BUF5 Q3ZCM7	TBB5_HUMAN TBB1_HUMAN TBB2A_HUMAN TBB2B_HUMAN TBB3_HUMAN TBB4A_HUMAN TBB4B_HUMAN TBB6_HUMAN TBB8_HUMAN	INHIBITOR			SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	6	DRUG MATRIX
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	6.27	DRUG MATRIX

External reference:

ID	Source
4023981	VUID
N0000021986	NUI
D01935	KEGG_DRUG
125317-39-7	SECONDARY_CAS_RN
4020895	VANDF
4023981	VANDF
C0078257	UMLSCUI
CHEBI:480999	CHEBI
GDF	PDB_CHEM_ID
CHEMBL553025	ChEMBL_ID
CHEMBL538943	ChEMBL_ID
CHEMBL3039595	ChEMBL_ID
D000077235	MESH_DESCRIPTOR_UI
DB00361	DRUGBANK_ID
7105	IUPHAR_LIGAND_ID
6054	INN_ID
Q6C979R91Y	UNII
5311497	PUBCHEM_CID
114527	RXNORM
2135	MMSL
46388	MMSL
5676	MMSL
d03810	MMSL
004380	NDDF
004381	NDDF
108792008	SNOMEDCT_US
108794009	SNOMEDCT_US
372541004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vinorelbine	HUMAN PRESCRIPTION DRUG LABEL	1	25021-204	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	27 sections
Vinorelbine	HUMAN PRESCRIPTION DRUG LABEL	1	45963-607	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	19 sections
Vinorelbine	HUMAN PRESCRIPTION DRUG LABEL	1	45963-607	INJECTION, SOLUTION	10 mg	INTRAVENOUS	ANDA	19 sections